Monograph Details
|
|
Musculoskeletal Disorders
> Bone disorders
|
|
DIDRONEL |
| Manufacturer |
|
Procter & Gamble Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Diphosphonate. |
| Generic Name |
|
Etidronate disodium 200mg, 400mg+; tabs; +scored. |
| Indications |
|
Treatment of symptomatic Paget's disease of bone. Prevention and treatment of heterotopic ossification after total hip replacement or due to spinal cord injury. |
| Children |
|
Not recommended (see literature). |
| Adults |
|
Give once daily (preferred) or in divided doses at least 2hrs before or after food. Paget's: initially 5–10mg/kg per day; max 6 months (if ineffective, or if rapid bone turnover must be suppressed or to reduce elevated cardiac output: 11–20mg/kg per day; max 3 months). May retreat after 3 etidronate-free months if evidence of active disease process exists. Heterotopic ossification: hip replacement: 20mg/kg per day for 1 month before and 3 months after surgery; spinal cord injury: 20mg/kg per day for 2 weeks, then 10mg/kg per day for 10 weeks. |
| Contraindications |
|
Clinically overt osteomalacia. |
| Precautions |
|
Ensure adequate calcium and Vit. D intake. Enterocolitis. Renal dysfunction: reduce dose. Bone fractures. Osteolytic lesions. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Calcium, aluminum- or magnesium-containing antacids, iron, other divalent cations reduce absorption (separate dosing by >2hrs). Monitor warfarin. |
| Adverse Reactions |
|
GI disturbances, musculoskeletal pain (may be severe); osteomalacia and increased fracture risk in chronic use or high doses; others. |
| How Supplied |
|
Tabs—60 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
